Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
Objectives To assess the effectiveness of Neuroaspis plp10 nutritional supplement when added to interferon (IFN)-β treatment in patients with relapsing-remitting multiple sclerosis (RRMS).Design A 30-month phase III multicentre, randomised, double-blind, placebo-controlled trial. Randomisation strat...
Hoofdauteurs: | , , , , , , , , , , , , , |
---|---|
Formaat: | Artikel |
Taal: | English |
Gepubliceerd in: |
BMJ Publishing Group
2022-11-01
|
Reeks: | BMJ Neurology Open |
Online toegang: | https://neurologyopen.bmj.com/content/4/2/e000334.full |